S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in

NYSE:ZYME - Zymeworks Stock Price, Forecast & News

$49.80
+2.08 (+4.36 %)
(As of 01/22/2020 04:00 PM ET)
Today's Range
$46.94
Now: $49.80
$52.75
50-Day Range
$39.66
MA: $44.63
$49.12
52-Week Range
$14.05
Now: $49.80
$52.75
Volume1.36 million shs
Average Volume554,412 shs
Market Capitalization$1.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.02 million
Book Value$5.64 per share

Profitability

Net Income$-36,560,000.00
Net Margins-112.95%

Miscellaneous

Employees180
Market Cap$1.96 billion
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.


Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.06. The firm earned $7.86 million during the quarter, compared to analysts' expectations of $7.77 million. Zymeworks had a negative net margin of 112.95% and a negative return on equity of 25.72%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

11 Wall Street analysts have issued 1 year target prices for Zymeworks' shares. Their forecasts range from $23.00 to $65.00. On average, they expect Zymeworks' stock price to reach $46.27 in the next twelve months. This suggests that the stock has a possible downside of 7.1%. View Analyst Price Targets for Zymeworks.

What is the consensus analysts' recommendation for Zymeworks?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks.

Has Zymeworks been receiving favorable news coverage?

Media headlines about ZYME stock have been trending positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zymeworks earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Zymeworks.

Are investors shorting Zymeworks?

Zymeworks saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 529,100 shares, an increase of 9.1% from the December 15th total of 485,000 shares. Based on an average daily volume of 359,800 shares, the short-interest ratio is currently 1.5 days. Currently, 1.7% of the shares of the company are short sold. View Zymeworks' Current Options Chain.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of of retail and institutional investors. Top institutional investors include DAVENPORT & Co LLC (0.02%), AE Wealth Management LLC (0.01%), HWG Holdings LP (0.01%) and Steward Partners Investment Advisory LLC (0.00%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly and Neil A Klompas. View Institutional Ownership Trends for Zymeworks.

Which institutional investors are buying Zymeworks stock?

ZYME stock was acquired by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, AE Wealth Management LLC, HWG Holdings LP and Steward Partners Investment Advisory LLC. View Insider Buying and Selling for Zymeworks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $49.80.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $1.96 billion and generates $53.02 million in revenue each year. The company earns $-36,560,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Zymeworks employs 180 workers across the globe.View Additional Information About Zymeworks.

What is Zymeworks' official website?

The official website for Zymeworks is http://www.zymeworks.com/.

How can I contact Zymeworks?

Zymeworks' mailing address is 540-1385 WEST 8TH AVENUE, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (NYSE ZYME)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Neutral Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel